NO832811L - Fremgangsmaate ved fremstilling av anti-tumor glykoproteiner - Google Patents
Fremgangsmaate ved fremstilling av anti-tumor glykoproteinerInfo
- Publication number
- NO832811L NO832811L NO832811A NO832811A NO832811L NO 832811 L NO832811 L NO 832811L NO 832811 A NO832811 A NO 832811A NO 832811 A NO832811 A NO 832811A NO 832811 L NO832811 L NO 832811L
- Authority
- NO
- Norway
- Prior art keywords
- tumor
- molecular weight
- glycoprotein
- cells
- cbx
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 36
- 238000000034 method Methods 0.000 title claims description 39
- 238000002360 preparation method Methods 0.000 title description 4
- 210000004027 cell Anatomy 0.000 claims abstract description 56
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 43
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 43
- 239000012228 culture supernatant Substances 0.000 claims abstract description 26
- 241001465754 Metazoa Species 0.000 claims abstract description 18
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 12
- 210000002950 fibroblast Anatomy 0.000 claims abstract description 10
- 208000032839 leukemia Diseases 0.000 claims abstract description 10
- 230000003307 reticuloendothelial effect Effects 0.000 claims abstract description 10
- 102100032920 Chromobox protein homolog 2 Human genes 0.000 claims description 10
- 101000797586 Homo sapiens Chromobox protein homolog 2 Proteins 0.000 claims description 10
- 230000015556 catabolic process Effects 0.000 claims description 10
- 238000006731 degradation reaction Methods 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 101710186708 Agglutinin Proteins 0.000 claims description 8
- 102100032902 Chromobox protein homolog 3 Human genes 0.000 claims description 8
- 101000797578 Homo sapiens Chromobox protein homolog 3 Proteins 0.000 claims description 8
- 101710146024 Horcolin Proteins 0.000 claims description 8
- 101710189395 Lectin Proteins 0.000 claims description 8
- 101710179758 Mannose-specific lectin Proteins 0.000 claims description 8
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 claims description 8
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 claims description 8
- 240000003864 Ulex europaeus Species 0.000 claims description 8
- 235000010730 Ulex europaeus Nutrition 0.000 claims description 8
- 239000000910 agglutinin Substances 0.000 claims description 8
- 239000004094 surface-active agent Substances 0.000 claims description 6
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 claims description 6
- -1 thiol compound Chemical class 0.000 claims description 6
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical compound OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 3
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 238000000354 decomposition reaction Methods 0.000 claims description 2
- 229910021645 metal ion Inorganic materials 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 229920002113 octoxynol Polymers 0.000 claims description 2
- 238000002523 gelfiltration Methods 0.000 claims 3
- 238000005185 salting out Methods 0.000 claims 3
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine group Chemical group P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 claims 1
- VICYBMUVWHJEFT-UHFFFAOYSA-N dodecyltrimethylammonium ion Chemical compound CCCCCCCCCCCC[N+](C)(C)C VICYBMUVWHJEFT-UHFFFAOYSA-N 0.000 claims 1
- 229910052987 metal hydride Inorganic materials 0.000 claims 1
- 150000004681 metal hydrides Chemical class 0.000 claims 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims 1
- FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 claims 1
- 230000000593 degrading effect Effects 0.000 abstract description 2
- 102100032919 Chromobox protein homolog 1 Human genes 0.000 description 40
- 101000797584 Homo sapiens Chromobox protein homolog 1 Proteins 0.000 description 40
- 238000006243 chemical reaction Methods 0.000 description 36
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 23
- 239000000203 mixture Substances 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 13
- 239000007858 starting material Substances 0.000 description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000008363 phosphate buffer Substances 0.000 description 11
- 235000000346 sugar Nutrition 0.000 description 11
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 244000309466 calf Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 229910002091 carbon monoxide Inorganic materials 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 150000008273 hexosamines Chemical class 0.000 description 4
- 150000002402 hexoses Chemical class 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 4
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 125000005629 sialic acid group Chemical group 0.000 description 4
- 239000012475 sodium chloride buffer Substances 0.000 description 4
- 239000012064 sodium phosphate buffer Substances 0.000 description 4
- MYKOKMFESWKQRX-UHFFFAOYSA-N 10h-anthracen-9-one;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 MYKOKMFESWKQRX-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 101100020289 Xenopus laevis koza gene Proteins 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 210000000540 fraction c Anatomy 0.000 description 3
- HHIVCXLCMPHUSC-UHFFFAOYSA-N hydron;1h-indol-1-ium;sulfate Chemical compound OS(O)(=O)=O.C1=CC=C2NC=CC2=C1 HHIVCXLCMPHUSC-UHFFFAOYSA-N 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- 108010047620 Phytohemagglutinins Proteins 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000002196 fr. b Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 239000002563 ionic surfactant Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- HOVAGTYPODGVJG-VEIUFWFVSA-N methyl alpha-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000001885 phytohemagglutinin Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- UNUFVVHXFJOAMX-UHFFFAOYSA-N 1-n,1-n,1-n',1-n',1-n",1-n"-hexaethyl-2-phosphanylethane-1,1,1-triamine Chemical compound CCN(CC)C(CP)(N(CC)CC)N(CC)CC UNUFVVHXFJOAMX-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical class C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-N cyanic acid Chemical class OC#N XLJMAIOERFSOGZ-UHFFFAOYSA-N 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- RLFDRKYCDBYELB-UHFFFAOYSA-N didecyl sulfate;sodium Chemical compound [Na].CCCCCCCCCCOS(=O)(=O)OCCCCCCCCCC RLFDRKYCDBYELB-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- XJWSAJYUBXQQDR-UHFFFAOYSA-M dodecyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)C XJWSAJYUBXQQDR-UHFFFAOYSA-M 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 239000013542 high molecular weight contaminant Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 150000003003 phosphines Chemical group 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940054541 urex Drugs 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/91—Cell lines ; Processes using cell lines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57135852A JPS5925332A (ja) | 1982-08-04 | 1982-08-04 | 抗腫瘍性糖蛋白質の製法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO832811L true NO832811L (no) | 1984-02-06 |
Family
ID=15161271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO832811A NO832811L (no) | 1982-08-04 | 1983-08-03 | Fremgangsmaate ved fremstilling av anti-tumor glykoproteiner |
Country Status (21)
| Country | Link |
|---|---|
| JP (1) | JPS5925332A (fr) |
| KR (1) | KR840006127A (fr) |
| AU (1) | AU1759283A (fr) |
| BE (1) | BE897470A (fr) |
| BR (1) | BR8304143A (fr) |
| DD (1) | DD213440A5 (fr) |
| DE (1) | DE3328239A1 (fr) |
| DK (1) | DK356483A (fr) |
| FI (1) | FI832776A (fr) |
| FR (1) | FR2531435A1 (fr) |
| GB (1) | GB2125048A (fr) |
| GR (1) | GR78638B (fr) |
| IT (1) | IT8348806A0 (fr) |
| LU (1) | LU84946A1 (fr) |
| NL (1) | NL8302765A (fr) |
| NO (1) | NO832811L (fr) |
| PL (1) | PL243306A1 (fr) |
| PT (1) | PT77154B (fr) |
| SE (1) | SE8304276L (fr) |
| YU (1) | YU161983A (fr) |
| ZA (1) | ZA835680B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2161813B (en) * | 1984-07-20 | 1988-07-13 | Michiko Koga | Anti-tumor agent |
| JP3439490B2 (ja) * | 1992-09-28 | 2003-08-25 | 株式会社林原生物化学研究所 | 蛋白質とその蛋白質をコードするｄｎａ並びにその蛋白質の製造方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2073293B1 (fr) * | 1969-12-31 | 1973-01-12 | Pasteur Institut | |
| WO1980002375A1 (fr) * | 1977-09-23 | 1980-11-13 | Hem Res Inc | Interferons d'origine animale et de grande purete |
-
1982
- 1982-08-04 JP JP57135852A patent/JPS5925332A/ja active Pending
-
1983
- 1983-07-28 KR KR1019830003525A patent/KR840006127A/ko not_active Application Discontinuation
- 1983-07-29 GB GB08320547A patent/GB2125048A/en not_active Withdrawn
- 1983-08-01 GR GR72099A patent/GR78638B/el unknown
- 1983-08-02 BR BR8304143A patent/BR8304143A/pt unknown
- 1983-08-02 DD DD83253631A patent/DD213440A5/de unknown
- 1983-08-02 FI FI832776A patent/FI832776A/fi not_active Application Discontinuation
- 1983-08-03 PT PT77154A patent/PT77154B/pt unknown
- 1983-08-03 YU YU01619/83A patent/YU161983A/xx unknown
- 1983-08-03 ZA ZA835680A patent/ZA835680B/xx unknown
- 1983-08-03 NO NO832811A patent/NO832811L/no unknown
- 1983-08-03 IT IT8348806A patent/IT8348806A0/it unknown
- 1983-08-04 LU LU84946A patent/LU84946A1/fr unknown
- 1983-08-04 SE SE8304276A patent/SE8304276L/xx not_active Application Discontinuation
- 1983-08-04 PL PL24330683A patent/PL243306A1/xx unknown
- 1983-08-04 NL NL8302765A patent/NL8302765A/nl not_active Application Discontinuation
- 1983-08-04 DE DE19833328239 patent/DE3328239A1/de not_active Withdrawn
- 1983-08-04 DK DK356483A patent/DK356483A/da not_active Application Discontinuation
- 1983-08-04 AU AU17592/83A patent/AU1759283A/en not_active Abandoned
- 1983-08-04 FR FR8312892A patent/FR2531435A1/fr not_active Withdrawn
- 1983-08-04 BE BE0/211308A patent/BE897470A/fr not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DD213440A5 (de) | 1984-09-12 |
| KR840006127A (ko) | 1984-11-22 |
| NL8302765A (nl) | 1984-03-01 |
| IT8348806A0 (it) | 1983-08-03 |
| BR8304143A (pt) | 1984-03-13 |
| DE3328239A1 (de) | 1984-02-16 |
| LU84946A1 (fr) | 1983-12-28 |
| YU161983A (en) | 1986-02-28 |
| PL243306A1 (en) | 1984-08-27 |
| DK356483A (da) | 1984-02-05 |
| BE897470A (fr) | 1984-02-06 |
| FR2531435A1 (fr) | 1984-02-10 |
| JPS5925332A (ja) | 1984-02-09 |
| FI832776A0 (fi) | 1983-08-02 |
| GR78638B (fr) | 1984-09-27 |
| SE8304276D0 (sv) | 1983-08-04 |
| DK356483D0 (da) | 1983-08-04 |
| GB2125048A (en) | 1984-02-29 |
| SE8304276L (sv) | 1984-02-05 |
| FI832776A (fi) | 1984-02-05 |
| ZA835680B (en) | 1984-08-29 |
| PT77154A (en) | 1983-09-01 |
| GB8320547D0 (en) | 1983-09-01 |
| PT77154B (en) | 1986-01-28 |
| AU1759283A (en) | 1984-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4708948A (en) | Substantially purified tumor growth inhibitory factor | |
| AU590872B2 (en) | Neovascularization inhibitors and methods for their production and use | |
| CN106565836B (zh) | 高亲和力的可溶性pdl-1分子 | |
| AU590543B2 (en) | Purification of native colony stimulating factor-1 | |
| US4404188A (en) | Purified Mullerian Inhibiting Substance and method of purification | |
| JPH04504105A (ja) | フォリスタチンおよびその精製法 | |
| AU724940B2 (en) | Protein which induces interferon-gamma production by immunocompetent cell | |
| CN110650746A (zh) | 生物活性复合物的制备 | |
| DE3587526T2 (de) | Serinproteaseinhibitoren und isolierungsverfahren dazu. | |
| DE3687097T2 (de) | Therapeutisches mittel zur behandlung haematopoietischer krankheiten. | |
| US4510131A (en) | Purified Mullerian Inhibiting Substance and method of use | |
| WO1996032123A1 (fr) | Preparations pharmaceutiques derivees du gui de coree | |
| DE69230879T2 (de) | Verwendung von Hepatocyten-Wachstumsfaktoren zur Herstellung eines Vermehrungssystems für Hematopoietische Stammzellen | |
| US5547674A (en) | Pharmaceutical preparations derived from European mistletoe | |
| JPS6219525A (ja) | 植物起源の生物活性物質の製造法および同物質含有組成物 | |
| JPH0550273B2 (fr) | ||
| NO832811L (no) | Fremgangsmaate ved fremstilling av anti-tumor glykoproteiner | |
| Ferrari et al. | Toxicity and activity of purified trichosanthin | |
| JP2001508435A (ja) | ミエロペプチドおよびそれらの医療用途 | |
| EP0136093A2 (fr) | Facteurs anti-cancereux | |
| US7309501B2 (en) | Conditioned media to inhibit growth of tumor cells | |
| JPS59141519A (ja) | 制ガン作用を有する蛋白質 | |
| GB2042558A (en) | Interferon inducers, methods for their preparation, pharmaceutical compositions containing them and their use as medicaments | |
| JP3677054B2 (ja) | ヒトｔ細胞白血病ウィルス感染・増殖抑制剤 | |
| NO850152L (no) | Fremgangsmaate ved fremstilling av human, endogen cancerregulerende faktor. |